KR20220101071A - 새로운 화합물 - Google Patents
새로운 화합물 Download PDFInfo
- Publication number
- KR20220101071A KR20220101071A KR1020227008929A KR20227008929A KR20220101071A KR 20220101071 A KR20220101071 A KR 20220101071A KR 1020227008929 A KR1020227008929 A KR 1020227008929A KR 20227008929 A KR20227008929 A KR 20227008929A KR 20220101071 A KR20220101071 A KR 20220101071A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- imidazol
- urea
- phenyl
- thienylsulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201913603A GB201913603D0 (en) | 2019-09-20 | 2019-09-20 | New compounds |
| GB1913603.5 | 2019-09-20 | ||
| PCT/GB2020/052261 WO2021053344A1 (en) | 2019-09-20 | 2020-09-18 | New compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220101071A true KR20220101071A (ko) | 2022-07-19 |
Family
ID=68425648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227008929A Pending KR20220101071A (ko) | 2019-09-20 | 2020-09-18 | 새로운 화합물 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12435072B2 (https=) |
| EP (1) | EP4031240A1 (https=) |
| JP (2) | JP7771049B2 (https=) |
| KR (1) | KR20220101071A (https=) |
| CN (1) | CN114786774A (https=) |
| AU (1) | AU2020351301B2 (https=) |
| BR (1) | BR112022003130A2 (https=) |
| CA (1) | CA3152218A1 (https=) |
| CL (1) | CL2022000656A1 (https=) |
| CO (1) | CO2022003091A2 (https=) |
| GB (1) | GB201913603D0 (https=) |
| IL (1) | IL291172A (https=) |
| MX (2) | MX2022003286A (https=) |
| PH (1) | PH12022550564A1 (https=) |
| WO (1) | WO2021053344A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202004094D0 (en) * | 2020-03-20 | 2020-05-06 | Vicore Pharma Ab | New compounds and uses |
| GB202013721D0 (en) * | 2020-09-01 | 2020-10-14 | Vicore Pharma Ab | New compounds |
| GB202104033D0 (en) * | 2021-03-23 | 2021-05-05 | Vicore Pharma Ab | New compounds |
| GB2605148A (en) * | 2021-03-23 | 2022-09-28 | Vicore Pharma Ab | New compounds |
| EP4313953A1 (en) * | 2021-03-23 | 2024-02-07 | Vicore Pharma AB | Selective angiotensin ii receptor ligands |
| GB202113583D0 (en) * | 2021-09-23 | 2021-11-10 | Vicore Pharma Ab | New compounds |
| GB202104038D0 (en) * | 2021-03-23 | 2021-05-05 | Vicore Pharma Ab | New compounds |
| MX2024000518A (es) * | 2021-07-09 | 2024-01-31 | Vicore Pharma Ab | Nuevos compuestos selectivos de angiotensina ii. |
| CA3247073A1 (en) * | 2022-04-06 | 2025-02-03 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | AT2R AGONIST |
| IE20230600A3 (en) | 2022-12-22 | 2025-09-24 | Vicore Pharma Ab | A method of treating a patient diagnosed with an interstitial lung disease |
| WO2024149712A1 (en) * | 2023-01-09 | 2024-07-18 | Vicore Pharma Ab | Selective angiotensin ii compounds |
| CN119504723A (zh) * | 2023-08-25 | 2025-02-25 | 武汉人福创新药物研发中心有限公司 | 作为at2r激动剂的噻吩磺酰基氨基甲酸酯 |
| WO2025146172A1 (zh) * | 2024-01-03 | 2025-07-10 | 武汉人福创新药物研发中心有限公司 | 一种并环类化合物作为at2r激动剂 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5198438A (en) * | 1991-05-07 | 1993-03-30 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| US5312820A (en) | 1992-07-17 | 1994-05-17 | Merck & Co., Inc. | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines |
| US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| SE9800550D0 (sv) | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| YU78601A (sh) | 1999-05-05 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže |
| DE19920815A1 (de) | 1999-05-05 | 2000-11-09 | Aventis Pharma Gmbh | 1-(p-Thienylbenzyl)-Imidazole als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| KR100938817B1 (ko) | 2001-05-31 | 2010-01-26 | 바이코어 파마 아베 | 안지오텐신 ⅱ 작용제로 유용한 삼중고리 화합물 |
| CA2449150C (en) | 2001-05-31 | 2011-07-12 | Vicore Pharma Ab | Tricyclic compounds useful as angiotensin ii agonists |
| WO2004046141A1 (en) | 2002-11-21 | 2004-06-03 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| AU2006235698B2 (en) | 2005-04-12 | 2012-03-29 | Vicore Pharma Ab | New tricyclic angiotensin II agonists |
| US8835471B2 (en) | 2010-06-11 | 2014-09-16 | Vicore Pharma Ab | Use of angiotensin II agonists |
| KR20150028761A (ko) * | 2011-12-16 | 2015-03-16 | 타릭스 파마슈티컬스 엘티디. | 섬유증 치료용 안지오텐신 |
| KR102230461B1 (ko) | 2013-03-15 | 2021-03-22 | 유니버시티 오브 써던 캘리포니아 | 엔지오텐신-관련 질환들의 치료를 위한 방법들, 화합물들 및 조성물들 |
| EP2832357A1 (en) | 2013-07-29 | 2015-02-04 | Charité - Universitätsmedizin Berlin | Selective AT2 receptor agonists for use in treatment of cachexia |
| BR112017012337A2 (pt) | 2014-12-12 | 2018-02-27 | Vicore Pharma Ab | Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação. |
| WO2016107879A2 (en) | 2014-12-30 | 2016-07-07 | Vicore Pharma Ab | New use of angiotensin ii receptor agonists |
| CN107405406A (zh) * | 2015-03-02 | 2017-11-28 | 维科尔药物公司 | 用于治疗肺纤维化的血管紧张素ii受体激动剂 |
| WO2017221012A1 (en) | 2016-06-21 | 2017-12-28 | Vicore Pharma Ab | Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity |
| AR108906A1 (es) * | 2016-06-29 | 2018-10-10 | Bristol Myers Squibb Co | Heterociclos de biarilmetilo |
| GB201710906D0 (en) | 2017-07-06 | 2017-08-23 | Vicore Pharma Ab | Compounds and methods for treating peripheral neuropathy |
-
2019
- 2019-09-20 GB GB201913603A patent/GB201913603D0/en not_active Ceased
-
2020
- 2020-09-18 WO PCT/GB2020/052261 patent/WO2021053344A1/en not_active Ceased
- 2020-09-18 CN CN202080065335.5A patent/CN114786774A/zh active Pending
- 2020-09-18 AU AU2020351301A patent/AU2020351301B2/en active Active
- 2020-09-18 PH PH1/2022/550564A patent/PH12022550564A1/en unknown
- 2020-09-18 EP EP20780297.6A patent/EP4031240A1/en active Pending
- 2020-09-18 BR BR112022003130A patent/BR112022003130A2/pt unknown
- 2020-09-18 MX MX2022003286A patent/MX2022003286A/es unknown
- 2020-09-18 US US17/761,670 patent/US12435072B2/en active Active
- 2020-09-18 KR KR1020227008929A patent/KR20220101071A/ko active Pending
- 2020-09-18 CA CA3152218A patent/CA3152218A1/en active Pending
- 2020-09-18 JP JP2022516299A patent/JP7771049B2/ja active Active
-
2022
- 2022-03-07 IL IL291172A patent/IL291172A/en unknown
- 2022-03-17 CL CL2022000656A patent/CL2022000656A1/es unknown
- 2022-03-17 MX MX2025000262A patent/MX2025000262A/es unknown
- 2022-03-17 CO CONC2022/0003091A patent/CO2022003091A2/es unknown
-
2025
- 2025-10-02 US US19/348,124 patent/US20260028333A1/en active Pending
- 2025-11-05 JP JP2025186669A patent/JP2026041728A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020351301A1 (en) | 2022-03-17 |
| EP4031240A1 (en) | 2022-07-27 |
| JP2022549086A (ja) | 2022-11-24 |
| AU2020351301B2 (en) | 2026-02-12 |
| JP7771049B2 (ja) | 2025-11-17 |
| IL291172A (en) | 2022-05-01 |
| CN114786774A (zh) | 2022-07-22 |
| BR112022003130A2 (pt) | 2022-05-17 |
| CL2022000656A1 (es) | 2022-11-04 |
| GB201913603D0 (en) | 2019-11-06 |
| US20260028333A1 (en) | 2026-01-29 |
| PH12022550564A1 (en) | 2023-03-20 |
| US20220388994A1 (en) | 2022-12-08 |
| US12435072B2 (en) | 2025-10-07 |
| CA3152218A1 (en) | 2021-03-25 |
| MX2022003286A (es) | 2022-04-12 |
| CO2022003091A2 (es) | 2022-04-19 |
| WO2021053344A1 (en) | 2021-03-25 |
| MX2025000262A (es) | 2025-02-10 |
| JP2026041728A (ja) | 2026-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12435072B2 (en) | Compounds | |
| US11390616B2 (en) | Apelin receptor agonists and methods of use | |
| KR20140040774A (ko) | 이미다조피리딘 화합물 | |
| US12441718B2 (en) | Selective angiotensin II compounds | |
| IL300582A (en) | New compounds for use in the treatment of angiotensin II-related diseases | |
| GB2605148A (en) | New compounds | |
| WO2024149712A1 (en) | Selective angiotensin ii compounds | |
| US20240197685A1 (en) | Selective angiotensin ii receptor ligands | |
| WO2022200785A1 (en) | Selective angiotensin ii receptor ligands | |
| EA048147B1 (ru) | Новые соединения | |
| CN117222624A (zh) | 选择性血管紧张素ii受体配体 | |
| CN117916229A (zh) | 新型选择性血管紧张素ii化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |